The mean scores of the BRCA1/2-negative groups (16.1 for Group 2 and 12.8 for Group 5) were also similar to those from the original report on the MICRA (12.7–15.1) [4] and a previous study of patients with ovarian cancer (14.9–17.1) [7]. This evidence concerns the gene BRCA1 and ovarian cancer.